120
Views
4
CrossRef citations to date
0
Altmetric
Articles

Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab

, B.Sc, M.Sc ORCID Icon, , MD CSCN (EEG) FAES ORCID Icon & , MA MB BChir FRCSEd (Ophth) FRCSC ORCID Icon
Pages 26-29 | Received 15 Apr 2018, Accepted 18 Jan 2019, Published online: 27 Feb 2019

References

  • Finnis MF, Jayawant S. Juvenile myasthenia gravis: a paediatric perspective. Autoimmune Dis. 2011;1:1. doi:10.4061/2011/404101.
  • Nowak RJ, DiCapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord. 2011;4(5):259–266. doi:10.1177/1756285611411503.
  • Takahashi Y, Sugiyama M, Ueda Y, et al. Childhood-onset anti-MuSK antibody positive myasthenia gravis demonstrates a distinct clinical course. Brain Dev. 2012;34(9):784–786.doi:10.1016/j.braindev.2011.12.014.
  • Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126(10):2304–2311.doi:10.1093/brain/awg223.
  • Huang YC, Yeh JH, Chiu HC, Chen WH. Clinical characteristics of MuSK antibody-positive myasthenia gravis in Taiwan. J Formos Med Assoc. 2008;107(7):572–575. doi:10.1016/S0929-6646(08)60171-0.
  • Selvan V. Single-fiber EMG: a review. Ann Indian Acad Neurol. 2011;14(1):64. doi:10.4103/0972-2327.78058.
  • Pasnoor M, Gi W, Nations S, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle and Nerve. 2010;41(3):370–374.doi:10.1002/mus.21533.
  • Anlar B, Yilmaz V, Saruhan-Direskeneli G. Long remission in muscle-specific kinase antibody-positive juvenile myasthenia. Pediatr Neurol. 2009;40(6):455–456. doi:10.1016/j.pediatrneurol.2008.11.014.
  • Skjei KL, Lennon VA, Kuntz NL. Muscle specific kinase autoimmune myasthenia gravis in children: a case series. Neuromuscul Disord. 2013;23(11):874–882. doi:10.1016/j.nmd.2013.07.010.
  • Díaz-Manera J, Martínez-Hernández E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology. 2012;78(3):189–193.doi:10.1212/WNL.0b013e3182407982.
  • Govindarajan R, Iyadurai SJ, Connolly A, Zaidman C. Selective response to rituximab in a young child with MuSK-associated myasthenia gravis. Neuromuscul Disord. 2015;25(8):651–652. doi:10.1016/j.nmd.2015.03.014.
  • Barraud C, Desguerre I, Barnerias C, Gitiaux C, Boulay C, Chabrol B. Clinical features and evolution of juvenile myasthenia gravis in a French cohort. Muscle and Nerve. 2018;57(4):603–609. doi:10.1002/mus.25965.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.